Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.71
NAS:ALNY's Cash to Debt is ranked lower than
62% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:ALNY: 5.71 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ALNY' s Cash to Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 5.71
Equity to Asset 0.80
NAS:ALNY's Equity to Asset is ranked higher than
65% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALNY: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ALNY' s Equity to Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.59 Max: 0.92
Current: 0.8
-0.99
0.92
Interest Coverage N/A
NAS:ALNY's Interest Coverage is ranked lower than
54% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 1
Z-Score: 12.11
M-Score: -3.42
WACC vs ROIC
17.31%
-127.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1247.35
NAS:ALNY's Operating margin (%) is ranked lower than
78% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:ALNY: -1247.35 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ALNY' s Operating margin (%) Range Over the Past 10 Years
Min: -1247.35  Med: -164.88 Max: -28.95
Current: -1247.35
-1247.35
-28.95
Net-margin (%) -1204.90
NAS:ALNY's Net-margin (%) is ranked lower than
78% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:ALNY: -1204.90 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ALNY' s Net-margin (%) Range Over the Past 10 Years
Min: -1204.9  Med: -143.7 Max: -27.3
Current: -1204.9
-1204.9
-27.3
ROE (%) -28.70
NAS:ALNY's ROE (%) is ranked higher than
53% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:ALNY: -28.70 )
Ranked among companies with meaningful ROE (%) only.
NAS:ALNY' s ROE (%) Range Over the Past 10 Years
Min: -84.12  Med: -34.05 Max: -13.08
Current: -28.7
-84.12
-13.08
ROA (%) -25.57
NAS:ALNY's ROA (%) is ranked higher than
52% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:ALNY: -25.57 )
Ranked among companies with meaningful ROA (%) only.
NAS:ALNY' s ROA (%) Range Over the Past 10 Years
Min: -48.05  Med: -21.88 Max: -5.01
Current: -25.57
-48.05
-5.01
ROC (Joel Greenblatt) (%) -1088.36
NAS:ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:ALNY: -1088.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ALNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2120.98  Med: -430.03 Max: -149.42
Current: -1088.36
-2120.98
-149.42
Revenue Growth (3Y)(%) -28.30
NAS:ALNY's Revenue Growth (3Y)(%) is ranked lower than
78% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:ALNY: -28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ALNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -5.9 Max: 108
Current: -28.3
0
108
EBITDA Growth (3Y)(%) 11.20
NAS:ALNY's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ALNY: 11.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ALNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: -4.2 Max: 65.3
Current: 11.2
-64.8
65.3
EPS Growth (3Y)(%) 17.80
NAS:ALNY's EPS Growth (3Y)(%) is ranked higher than
73% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:ALNY: 17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ALNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.8  Med: 1.8 Max: 52.8
Current: 17.8
-66.8
52.8
» NAS:ALNY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALNY Guru Trades in Q3 2015

Vanguard Health Care Fund 7,355,914 sh (+20.69%)
Pioneer Investments 632,698 sh (+0.41%)
John Griffin 1,075,000 sh (unchged)
Jim Simons Sold Out
Mairs and Power Sold Out
» More
Q4 2015

ALNY Guru Trades in Q4 2015

Mairs and Power 2,300 sh (New)
George Soros 6,000 sh (New)
John Paulson 12,300 sh (New)
Vanguard Health Care Fund 7,583,610 sh (+3.10%)
John Griffin 1,075,000 sh (unchged)
Pioneer Investments Sold Out
» More
Q1 2016

ALNY Guru Trades in Q1 2016

Jim Simons 214,000 sh (New)
Vanguard Health Care Fund 8,512,270 sh (+12.25%)
John Paulson 12,300 sh (unchged)
John Griffin 1,075,000 sh (unchged)
Mairs and Power Sold Out
George Soros Sold Out
» More
Q2 2016

ALNY Guru Trades in Q2 2016

Dodge & Cox 2,516,669 sh (New)
John Paulson 19,300 sh (+56.91%)
John Griffin 1,320,000 sh (+22.79%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
Jim Simons 18,673 sh (-91.27%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:TSRO, NAS:UTHR, NAS:ALKS, NAS:GRFS, NAS:JAZZ, NAS:SGEN, NAS:IONS, NAS:ICPT, NAS:TECH, NAS:ACAD, NAS:EXEL, NAS:CBPO, NAS:GLPG, OTCPK:BTGGF, NYSE:XON, NAS:JUNO, NAS:RARE, OTCPK:SOLTF, NAS:SRPT, NAS:KITE » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" - the molecules that mediate RNAi - toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include paten, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.

Ratios

vs
industry
vs
history
P/B 6.09
ALNY's P/B is ranked lower than
67% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ALNY: 6.09 )
Ranked among companies with meaningful P/B only.
ALNY' s P/B Range Over the Past 10 Years
Min: 2.07  Med: 4.86 Max: 21.37
Current: 6.09
2.07
21.37
P/S 221.23
ALNY's P/S is ranked lower than
90% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. ALNY: 221.23 )
Ranked among companies with meaningful P/S only.
ALNY' s P/S Range Over the Past 10 Years
Min: 3.09  Med: 20.92 Max: 222.15
Current: 221.23
3.09
222.15
Current Ratio 12.58
ALNY's Current Ratio is ranked higher than
83% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. ALNY: 12.58 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.77 Max: 18.24
Current: 12.58
1.88
18.24
Quick Ratio 12.58
ALNY's Quick Ratio is ranked higher than
83% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ALNY: 12.58 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.77 Max: 18.24
Current: 12.58
1.88
18.24
Days Sales Outstanding 116.03
ALNY's Days Sales Outstanding is ranked lower than
78% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. ALNY: 116.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 116.03
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.50
ALNY's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ALNY: -17.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.8 Max: -1
Current: -17.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.67
ALNY's Price/Net Cash is ranked lower than
68% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. ALNY: 11.67 )
Ranked among companies with meaningful Price/Net Cash only.
ALNY' s Price/Net Cash Range Over the Past 10 Years
Min: 3.7  Med: 8.55 Max: 92.77
Current: 11.67
3.7
92.77
Price/Net Current Asset Value 11.06
ALNY's Price/Net Current Asset Value is ranked lower than
70% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ALNY: 11.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALNY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.54  Med: 8.59 Max: 82.06
Current: 11.06
3.54
82.06
Price/Tangible Book 6.08
ALNY's Price/Tangible Book is ranked lower than
59% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. ALNY: 6.08 )
Ranked among companies with meaningful Price/Tangible Book only.
ALNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.2  Med: 4.87 Max: 15.16
Current: 6.08
2.2
15.16
Price/Median PS Value 10.58
ALNY's Price/Median PS Value is ranked lower than
96% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. ALNY: 10.58 )
Ranked among companies with meaningful Price/Median PS Value only.
ALNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 0.96 Max: 10.3
Current: 10.58
0.16
10.3
Earnings Yield (Greenblatt) (%) -6.23
ALNY's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ALNY: -6.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.16  Med: 465.9 Max: 1781.6
Current: -6.23
-10.16
1781.6

More Statistics

Revenue (TTM) (Mil) $29.93
EPS (TTM) $ -4.24
Beta2.09
Short Percentage of Float15.58%
52-Week Range $49.96 - 110.75
Shares Outstanding (Mil)85.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 45 65 199
EPS ($) -5.14 -5.61 -1.53
EPS w/o NRI ($) -5.14 -5.61 -1.53
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ALNY

Headlines

Articles On GuruFocus.com
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 

More From Other Websites
2:35 am Alnylam Pharma reports positive initial results from ongoing Phase 1/2 study of ALN-GO1;... Sep 27 2016
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational... Sep 24 2016
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational... Sep 24 2016
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer Sep 21 2016
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer Sep 21 2016
Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK Sep 20 2016
Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK Sep 20 2016
Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK Sep 20 2016
[$$] Alnylam to brave Brexit and set up European HQ in UK Sep 19 2016
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change... Sep 19 2016
Alnylam Expands and Strengthens Management Team as it Plans for Commercialization Sep 19 2016
Alnylam Expands and Strengthens Management Team as it Plans for Commercialization Sep 19 2016
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016
Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1 Sep 08 2016
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational... Sep 07 2016
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational... Sep 07 2016
Alnylam to Webcast Presentations at Upcoming September Investor Conferences Sep 06 2016
Alnylam to Webcast Presentations at Upcoming September Investor Conferences Sep 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)